Journal
CLINICAL INFECTIOUS DISEASES
Volume 61, Issue 9, Pages 1432-1438Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ631
Keywords
host-directed therapy; tuberculosis; treatment; multi-drug resistant tuberculosis; repurposed drugs
Categories
Funding
- The Francis Crick Institute [10218] Funding Source: researchfish
- Wellcome Trust [104803/Z/14/Z] Funding Source: researchfish
- Wellcome Trust [104803/Z/14/Z] Funding Source: Wellcome Trust
- Wellcome Trust [104803] Funding Source: Medline
Ask authors/readers for more resources
Tuberculosis remains a global emergency causing an estimated 1.5 million deaths annually. For several decades the major focus of tuberculosis treatment has been on antibiotic development targeting Mycobacterium tuberculosis. The lengthy tuberculosis treatment duration and poor treatment outcomes associated with multi-drug resistant tuberculosis (MDR-TB) are of major concern. The sparse new tuberculosis drug pipeline and widespread emergence of MDR-TB signal an urgent need for more innovative interventions to improve treatment outcomes. Building on the historical Pasteur-Bechamp debates on the role of the microbe vs the host internal milieu in disease causation, we make the case for parallel investments into host-directed therapies (HDTs). A range of potential HDTs are now available which require evaluation in randomized controlled clinical trials as adjunct therapies for shortening the duration of tuberculosis therapy and improving treatment outcomes for drug-susceptible tuberculosis and MDR-TB. Funder initiatives that may enable further research into HDTs are described.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available